Rapport Therapeutics Inc (RAPP) Stock Price, Quote & News

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, includi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 321 8020

Website: www.rapportrx.com

Address:

99 High Street, Suite 2100, Boston, United States

Quantumup May. 12 at 5:14 PM

Stifel reiterated $RAPP Buy; $56, and said: We remain Buy rated on RAPP following their 1Q26 report, where notably, the RAP-219 ph2 results in bipolar mania are now expected in 4Q26 (1H27 previously). $PRAX BHVN MPLT VNDA ALKS JAZZ UCBJY $XENE Here's what else Stifel said in its note to investors: https://x.com/Quantumup1/status/2054248241332412799?s=20

0 · Reply

Stonkapedia May. 7 at 5:11 PM

$RAPP guess I fucked this up 😂

0 · Reply

Quantumup May. 7 at 1:19 PM

Raymond reiterated $RAPP Strong Buy; $66, and provided its thoughts on the stock. $XENE $PRAX BHVN MPLT VNDA JAZZ ALKS UCBJY Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2052377029060726819?s=20

0 · Reply

peloswing Apr. 30 at 7:09 PM

$RAPP has support at the previous highs from December, and the 50 DMA just slightly below, at $31.53. On a -19% pullback from the recent highs and looking like pretty good risk:reward here. - Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG - Earnings expected on May 11th in pre-market. Implied move of +/-13.88%

0 · Reply

BillionerOfKing Apr. 30 at 12:53 AM

$RAPP Current Stock Price: $32.98 Contracts to trade: $32.5 RAPP May 15 2026 Call Entry: $0.20 Exit: $0.33 ROI: 64% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

laaarsas Apr. 27 at 7:04 PM

$RAPP What is vibe like in here?

0 · Reply

SuperGreenToday Apr. 27 at 1:38 PM

$RAPP Share Price: $36.25 Contract Selected: Nov 20, 2026 $40 Calls Buy Zone: $5.39 – $6.66 Target Zone: $9.53 – $11.64 Potential Upside: 67% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SocioCobb Apr. 17 at 3:13 AM

$RAPP 👍

0 · Reply

MooseG Apr. 15 at 11:10 AM

$RAPP phase 3 hasnt started, when it does, data wont come out until end of 2027 early 2028. Has this gotten ahead of itself?

1 · Reply

Quantumup Apr. 14 at 6:36 PM

Raymond James (a/o 4/9)🏁 $RAPP and said: Initiate at Strong Buy, $66 PT; Building Rapport with RAP-219 in Bipolar Mania $XENE $PRAX BHVN MPLT VNDA JAZZ ALKS UCBJY Here's what else Raymond James had to say in its initiation report: https://x.com/Quantumup1/status/2044121544658694182?s=20

0 · Reply

Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)

May 7, 2026, 7:00 AM EDT - 6 days ago

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Apr 30, 2026, 3:11 PM EDT - 12 days ago

Modalités de mise à disposition du rapport financier annuel 2025

Apr 30, 2026, 11:45 AM EDT - 12 days ago

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

2026-04-21T20:39:03.000Z - 21 days ago

Rapport Therapeutics presents results from Phase 2a trial of RAP-219

Apr 21, 2026, 4:30 PM EDT - 21 days ago

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

2026-04-10T09:46:08.000Z - 4 weeks ago

Rapport Therapeutics initiated with a Strong Buy at Raymond James

2026-04-09T20:25:35.000Z - 4 weeks ago

Rapport Therapeutics initiated with a Strong Buy at Raymond James

2026-04-09T20:15:15.000Z - 4 weeks ago

Rapport Therapeutics initiated with a Strong Buy at Raymond James

Apr 8, 2026, 8:27 AM EDT - 5 weeks ago

Communiqué de mise à disposition du rapport financier annuel 2025

Apr 1, 2026, 9:00 AM EDT - 6 weeks ago

Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

Mar 30, 2026, 5:28 AM EDT - 6 weeks ago

CRCAM Toulouse 31 - Rapport financier annuel 2025

Mar 12, 2026, 3:00 AM EDT - 2 months ago

Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025

Mar 11, 2026, 9:20 AM EDT - 2 months ago

Rapport Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:15 PM EDT - 2 months ago

Rapport Therapeutics Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:20:46.000Z - 2 months ago

Rapport Therapeutics files automatic mixed securities shelf

2026-03-10T11:12:39.000Z - 2 months ago

Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)

2026-03-10T11:12:14.000Z - 2 months ago

Rapport Therapeutics sees cash runway into 2H29

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-03-09T11:26:16.000Z - 2 months ago

Rapport, Tenacia announce collaboration for RAP-219 in Greater China

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Mar 3, 2026, 3:10 PM EST - 2 months ago

Rapport Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:05 PM EST - 2 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

2026-02-02T11:00:09.000Z - 3 months ago

Rapport Therapeutics initiated with an Overweight at Wells Fargo

Jan 15, 2026, 10:00 PM EST - 4 months ago

Fantôme Rapport Launches in English — A Romance, Horror, and Mystery Adventure Aboard a Ghostly Luxury Liner

Jan 14, 2026, 2:15 PM EST - 4 months ago

Rapport Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T12:06:37.000Z - 4 months ago

Rapport Therapeutics plans to initiates its Phase 3 program for RAP-219

Jan 7, 2026, 7:00 AM EST - 4 months ago

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Dec 18, 2025, 7:00 AM EST - 5 months ago

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-09T11:10:15.000Z - 5 months ago

Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright

2025-12-05T14:10:20.000Z - 5 months ago

Rapport Therapeutics announces new data, post hox analysis on RAP-219

Dec 5, 2025, 9:00 AM EST - 5 months ago

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures

Nov 25, 2025, 7:00 AM EST - 6 months ago

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

2025-11-18T21:21:39.000Z - 6 months ago

Rapport Therapeutics initiated with a Buy at BTIG

Nov 17, 2025, 8:00 AM EST - 6 months ago

Rapport Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 1:20 PM EST - 6 months ago

Rapport Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-07T10:50:53.000Z - 6 months ago

Rapport Therapeutics price target raised to $80 from $77 at Citizens JMP

2025-11-06T12:13:00.000Z - 6 months ago

Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)

Nov 6, 2025, 7:00 AM EST - 6 months ago

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 7, 2025, 9:03 AM EDT - 7 months ago

Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation

Sep 17, 2025, 11:20 AM EDT - 8 months ago

Rapport Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

2025-09-16T10:15:20.000Z - 8 months ago

Rapport Therapeutics initiated with a Buy at Truist

2025-09-15T21:40:12.000Z - 8 months ago

Rapport Therapeutics director buys $1.03M in common stock

Sep 12, 2025, 5:11 AM EDT - 8 months ago

Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025

Sep 11, 2025, 4:05 PM EDT - 8 months ago

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 10, 2025, 2:22 PM EDT - 8 months ago

Rapport stock plunges 18% on Wednesday: what went wrong after 200% rally

Sep 9, 2025, 9:17 PM EDT - 8 months ago

Rapport Announces Pricing of Public Offering of Common Stock

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Rapport Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 10:54 AM EDT - 8 months ago

Rapport stock rockets nearly 200% today, but analysts warn of possible crash soon

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Rapport Therapeutics Transcript: Study Result

Sep 8, 2025, 6:00 AM EDT - 8 months ago

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Sep 5, 2025, 4:05 PM EDT - 8 months ago

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Jun 9, 2025, 10:00 AM EDT - 1 year ago

Rapport Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 10:30 AM EDT - 1 year ago

Rapport Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 3:00 PM EDT - 1 year ago

Rapport Therapeutics Transcript: Investor Day 2025

Jun 2, 2025, 2:45 PM EDT - 1 year ago

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

May 27, 2025, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 8, 2025, 1:30 PM EDT - 1 year ago

Rapport Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Apr 30, 2025, 11:45 AM EDT - 1 year ago

Mise à disposition du rapport financier annuel 2024

Apr 29, 2025, 11:00 AM EDT - 1 year ago

Rapport Therapeutics Transcript: JonesResearch Virtual CNS Day

Apr 18, 2025, 7:46 AM EDT - 1 year ago

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

Mar 21, 2025, 2:26 PM EDT - 1 year ago

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

Mar 21, 2025, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Mar 19, 2025, 10:30 AM EDT - 1 year ago

Rapport Therapeutics Transcript: Virtual CNS Forum

Mar 13, 2025, 12:14 PM EDT - 1 year ago

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 13, 2025, 3:00 AM EDT - 1 year ago

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 3:10 PM EST - 1 year ago

Rapport Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Jan 9, 2025, 9:12 AM EST - 1 year ago

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Jan 9, 2025, 7:00 AM EST - 1 year ago

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Dec 6, 2024, 12:01 PM EST - 1 year ago

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Nov 20, 2024, 11:00 AM EST - 1 year ago

Rapport Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 1:15 PM EST - 1 year ago

Rapport Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 7:00 AM EST - 1 year ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Nov 4, 2024, 7:00 AM EST - 1 year ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Sep 17, 2024, 2:35 AM EDT - 1 year ago

Rapport semestriel Pilier 3 - 30 juin 2024

Sep 5, 2024, 4:50 PM EDT - 1 year ago

Rapport Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Quantumup May. 12 at 5:14 PM

0 · Reply

Stonkapedia May. 7 at 5:11 PM

$RAPP guess I fucked this up 😂

0 · Reply

Quantumup May. 7 at 1:19 PM

0 · Reply

peloswing Apr. 30 at 7:09 PM

0 · Reply

BillionerOfKing Apr. 30 at 12:53 AM

0 · Reply

laaarsas Apr. 27 at 7:04 PM

$RAPP What is vibe like in here?

0 · Reply

SuperGreenToday Apr. 27 at 1:38 PM

0 · Reply

SocioCobb Apr. 17 at 3:13 AM

$RAPP 👍

0 · Reply

MooseG Apr. 15 at 11:10 AM

$RAPP phase 3 hasnt started, when it does, data wont come out until end of 2027 early 2028. Has this gotten ahead of itself?

1 · Reply

Quantumup Apr. 14 at 6:36 PM

0 · Reply

Cutlass Apr. 10 at 11:33 AM

$RAPP Quiet Creeper here - I noted the gap at 16, alert set to review at 17. ⏰

1 · Reply

notreload_ai Apr. 10 at 11:16 AM

Analysts see big upside in $URGN , $RAPP , and $MIST , driven by strong drugs, upcoming data, and underestimated market potential. https://notreload.xyz/xy/analysts-issue-buy-ratings-on-urgn-rapp-mist-stocks/

0 · Reply

DonCorleone77 Apr. 9 at 11:22 PM

$SLP $CARS $RAPP $BEEM $FGI AFTER-HOURS MOVERS: Currently Higher After Earnings: - Simulations Plus (SLP) up 14.7% Currently Also Higher: - Cars. com (CARS) up 1.5% after cutting headcount by 11%, affirming guidance - Rapport Therapeutics (RAPP) up 2.6% after being started at Strong Buy at Raymond James Currently Lower After Earnings: - Beam Global (BEEM) down 8.0% - FGI Industries (FGI) down 8.0% - WD-40 Company (WDFC) down 0.4%

0 · Reply

SuperGreenToday Apr. 1 at 1:45 PM

$RAPP Share Price: $32.21 Contract Selected: Nov 20, 2026 $15 Calls Buy Zone: $10.94 – $13.51 Target Zone: $18.84 – $23.03 Potential Upside: 63% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Mar. 28 at 12:20 AM

$RAPP RSI: 37.19, MACD: -0.1315 Vol: 1.15, MA20: 28.55, MA50: 28.09 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Hognose Mar. 25 at 12:31 PM

$RYTM better buy right now is $ASND and $RAPP

0 · Reply

Hognose Mar. 24 at 7:23 PM

$RAPP Buy or regret

0 · Reply

Quantumup Mar. 11 at 1:09 PM

BTIG⬆️the PT on $RAPP to $53 from $47 and reiterated at a Buy rating. $XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities. Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with $490.5M in cash and equiv, funding operations into 2H29.

0 · Reply

OpenOutcrier Mar. 9 at 12:26 PM

$RAPP (+6.5% pre) China rights deal backs new epilepsy, bipolar drug RAP-219 https://ooc.bz/l/95959

0 · Reply

notreload_ai Mar. 9 at 12:11 PM

$RAPP partners with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China. $20M upfront + up to $308M milestones and tiered royalties for epilepsy & bipolar treatment. https://notreload.xyz/rapport-tenacia-collaborate-on-rap-219-in-greater-china/

0 · Reply

Market Cap	1.84B
Revenue (ttm)	0.00
Net Income (ttm)	-111.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	300,900
Avg Vol	359,076
Day's Range	N/A - N/A
Shares Out	47.83M
Stochastic %K	58%
Beta	0.82
Analysts	Strong Sell
Price Target	$53.60